Inhibition of the *exo*- β -D-glucosaminidase CsxA by a *glucosamine*-configured castanospermine and an *amino*-australine analogue

Benjamin Pluvinage^b, Mariana G. Ghinet^c, Ryszard Brzezinski^c, Alisdair B. Boraston^b, and Keith A. Stubbs^{*^a}

^aChemistry M313, School of Biomedical, Biomolecular and Chemical Sciences, The University of Western Australia, 35 Stirling Hwy, Crawley, WA Australia, 6009. E-mail: kstubbs@cyllene.uwa.edu.au Tel: +61 8 6488 2725;

^bBiochemistry and Microbiology, University of Victoria, PO Box 3055 STN CSC, Victoria, BC, Canada, V8W 3P6

^cCentre d Étude et de Valorisation de la Diversité Microbienne, Département de Biologie, Université de Sherbrooke, Sherbrooke, QC, Canada, J1K 2R1

Experimental

General

¹H and ¹³C NMR spectra were recorded on a Bruker ARX500 (500 MHz for ¹H and 125 MHz for ¹³C) or a Bruker AV600 (600 MHz for ¹H and 150 MHz for ¹³C) (chemical shifts quoted relative to CD₃OD). Elemental analyses of all synthesized compounds used in enzyme assays were performed at the Australian National University Microanalytical Facility. Flash chromatography was performed on BDH silica gel with the specified solvents. Thin-layer chromatography (TLC) was effected on Merck silica gel 60 F₂₅₄ aluminium-backed plates that were stained by heating (>200 °C) with 5% sulfuric acid in EtOH. Percentage yields for chemical reactions as described are quoted only for those compounds that were purified by column chromatography, and purity was assessed by TLC or ¹H NMR spectroscopy.

6-Amino-6-deoxycastanospermine (3)

A saturated solution of ammonia in MeOH (2 ml) was added to the amine 9^1 (80 mg) in MeOH (3 ml) and the solution left to stand (r.t., 2 h). Concentration followed by flash chromatography of the residue (CH₂Cl₂/MeOH/NH₄OH 5:4:1) gave the desired triol **3** (45 mg, 95%). ¹H and ¹³C NMR spectra consistent with that found in the literature.¹

8-Azido-8-deoxyaustraline (10)

A saturated solution of ammonia in MeOH (2 ml) was added to the azide 8^1 (105 mg) in MeOH (3 ml) and the solution left to stand (r.t., 2 h). Concentration followed by flash chromatography of the residue (MeOH/EtOAc 1:4) gave the desired triol **10** (60 mg, 92%). R_f 0.25 (MeOH/EtOAc 1:4); $\delta_{\rm H}$ (600 MHz, CD₃OD): 4.24-4.22 (m, 2H, H1, H7), 3.84 (dd, J = 7.7, 8.9, 1H, H2), 3.56 (dd, J = 3.2, 12.7, 1H, H8) 3.27 (dd, J = 6.6, 1H, H8), 3.18 (dd, J = 4.0, 6.8, 1H, H7a), 4.36-4.33 (m, 1H, H5), 2.75-2.68 (m, 2H, H3, H5), 2.00-1.95 (m, 1H, H6), 1.92-1.85 (m, 1H, H6). $\delta_{\rm C}$ (150 MHz, CDCl₃): 81.3 (C2), 74.5 (C1), 73.8 (C7a), 71.2 (C7), 70.4 (C3), 54.4 (C5), 53.0 (C8), 37.3 (C6).

8-Amino-8-deoxyaustraline (4)

10% Palladium-on-carbon (20 mg) was added to solution of **10** (80 mg) in MeOH (5 ml) and the mixture stirred at room temperature under an atmosphere of nitrogen (1 atm, 3 h). The mixture was filtered through a pad of celite and concentrated to give **4** as a colourless oil (67 mg, 95%). R_f 0.45 (CH₂Cl₂/MeOH/NH₄OH 5:4:1); $\delta_{\rm H}$ (500 MHz, CD₃OD): 4.26-4.23 (m, 2H, H1, H7), 3.84 (dd, *J* = 7.6, 8.7, 1H, H2), 3.18 (dd, *J* = 4.1, 6.7, 1H, H7a), 3.12-3.08 (m, 1H, H5), 2.80 (dd, *J* = 5.2, 13.2, 1H, H8), 2.76-2.70, 2.62-2.58 (2m, 3H, H3, H5 , H8), (m, 1H, H3, H5), 2.02-1.98 (m, 1H, H6), 1.94-1.86 (m, 1H, H6). $\delta_{\rm C}$ (125 MHz, CDCl₃): 82.5 (C2), 74.9 (C1), 74.0 (C7a), 73.4 (C7), 70.6 (C3), 53.1 (C5), 44.8 (C8), 37.3 (C6). Anal. calcd for C₈H₁₆N₂O₃: C, 51.05; H, 8.57. Found: C, 51.22; H, 8.65%.

Kinetic Analysis of CsxA

The CsxA protein was produced and purified as described previously.² The protein was buffer exchanged into 5 mM sodium acetate, pH 5.5, by repeated washing in a 10 ml stirred ultrafiltration device using a 5K MWCO membrane (Millipore). All assays were carried out in triplicate at 37 °C for 60 minutes by using a stopped assay procedure in which the enzymatic reactions (50 μ L) were quenched by the addition of a 4-fold excess (200 µL) of quenching buffer (200 mM glycine, pH 10.75). Assays were initiated by the careful addition, via pipette, of enzyme (5 µL), and in all cases the final pH of the resulting quenched solution was greater than 10. Time-dependent assay of CsxA revealed that the enzyme was stable in its buffers over the period of the assay: 50 mM sodium acetate, pH 5.3. The progress of the reaction at the end of 60 minutes was determined by measuring the extent of 4-methylumbelliferone liberated as determined by fluorescence measurements using a BMG Labtech Spectrophotometer 96-well plate system and comparison to a standard curve of 4-methylumbelliferone under identical buffer conditions. Excitation and emission wavelengths of 368 and 450 nM were used, respectively, with 5 mm slit openings. CsxA was used in the inhibition assays at a concentration (µg/µL) of 0.0106, using 4-methylumbelliferyl 2-amino-2-deoxy-β-Dglucopyranoside³ as substrate. Both inhibitors were tested at six concentrations and K_i values were determined by linear regression of data from Dixon plots.

Crystallization and Structure Solution of CsxA

Crystallization experiments were performed as described by previously.⁴ Briefly, crystals were obtained at 18 °C in a crystallization solution containing 18% (v/v) polyethylene glycol 2K monomethylether, 20 mM CdSO₄ and 100 mM Tris-HCl, pH 7.5. Crystals were then soaked in the mother liquor lacking CdSO₄ for 2 hours followed by transfer of the crystals into the soaking solution supplemented with 5 mM inhibitor (**3** or **4**) for 1 hour. All crystals were cryoprotected by the addition of a progressive concentration of glycerol until 20% (v/v) and frozen at 113 K prior to X-ray diffraction analysis. Diffraction data were collected on a home detector (Rigaku R- 15Axis 4++ area detector coupled to an MM-002 X-ray generator with Osmic Blue optics and an Oxford Cryostream 700) or on beamline 9.1 at the Stanford Synchrotron Radiation Laboratory (*SSRL*) and processed with MOSFLM/SCALA.⁵ The complex structures were determined using the native CsxA structure as a starting point (PDB ID 2VZO). Coordinate files and restraint libraries for the inhibitors were produced using the prodrg2 server.^{6,7} The final

structures of the complexes were obtained by manual correction using COOT and refinement with REFMAC.^{8,9} Waters were added automatically using COOT and inspected manually. 5% of the reflections were flagged as "free" to monitor refinement procedures.¹⁰ Model validation was performed with SFCHECK and PROCHECK in the CCP4 suite.^{11,12} All statistics concerning the data collection and structure refinements are shown in Table 1.

- 1. R. H. Furneaux, G. J. Gainsford, J. M. Mason and P. C. Tyler, *Tetrahedron*, 1994, **50**, 2131-2160.
- 2. T. Fukamizo, A. Fleury, N. Cote, M. Mitsutomi and R. Brzezinski, *Glycobiology*, 2006, 16, 1064-1072.
- 3. K. R. Roeser and G. Legler, Biochim. Biophys. Acta, Enzymol., 1981, 657, 321-333.
- 4. A. L. van Bueren, M. G. Ghinet, K. Gregg, A. Fleury, R. Brzezinski and A. B. Boraston, *J. Mol. Biol.*, 2009, **385**, 131-139.
- 5. H. R. Powell, Acta Cryst. D Biol. Crystallogr., 1999, 55, 1690-1695.
- 6. A. W. Schuttelkopf and D. M. van Aalten, *Acta Crystallogr. D Biol. Crystallogr.*, 2004, **60**, 1355-1363.
- 7. D. M. van Aalten, R. Bywater, J. B. Findlay, M. Hendlich, R. W. Hooft and G. Vriend, *J Comput Aided Mol. Des.*, 1996, **10**, 255-262.
- 8. P. Emsley and K. Cowtan, Acta Cryst. D Biol. Crystallogr., 2004, 60, 2126-2132.
- 9. G. N. Murshudov, A. A. Vagin and E. J. Dodson, *Acta Cryst. D Biol. Crystallogr.*, 1997, **53**, 240-255.
- 10. A. T. Brunger, Nature, 1992, 355, 472-475.
- 11. A. A. Vaguine, J. Richelle and S. J. Wodak, Acta Cryst. D Biol. Crystallogr., 1999, 55, 191-205.
- 12. R. A. Laskowski, M. W. Macarthur, D. S. Moss and J. M. Thornton, J. Appl. Crystallogr., 1993, 26, 283-291.

	Complex with 3	Complex with 4
Data Collection		
Wavelength (Å)	0.98	1.54
Space Group	P2 ₁	P2 ₁
Cell Dimensions		
<i>a</i> , <i>b</i> , <i>c</i> (Å)	86.1, 121.8, 91.6	86.8, 122.0, 92.1
$\alpha, \beta, \gamma(\text{\AA})$	90.0, 90.5, 90.0	90.0, 90.7, 90.0
Resolution (Å)	50-2.30	20.00-2.40
	(2.42-2.30)	(2.53-2.40)
R _{sym} or R _{merge}	0.154 (0.395)	0.135 (0.319)
I/σI	4.9 (2.5)	5.5 (3.3)
Completeness (%)	99.1 (99.8)	97.5 (94.9)
Redundancy	3.1 (3.1)	2.6 (2.5)
No. of reflections	261,451	192,716
No. unique	83,030	72,891
Refinement	50.2.20	20.00.2.10
Resolution (A)	50-2.30	20.00-2.40
R _{work} /R _{free}	0.184/0.248	0.176/0.240
No. Of atoms		
Protein	6520 (A); 6532 (B)	6518 (A); 6512 (B)
Ligand	19 Cd^{2+} ; 13 inhibitor (A)	3 Cd^{2+} ; 13 inhibitor (A)
	13 inhibitor (B)	13 inhibitor (B)
Water	1206	1446
<i>B</i> -factors		
Protein	18.6 (A); 18.1 (B)	16.5 (A); 15.4 (B)
T : 1	$89.9 (Cd^{-1}); 1/.6 \text{ inhibitor}$	29.1 ($Cd^{2^{-1}}$); 17.6 inhibitor
Ligand	(A) 17.3 inhibitor (B)	(A) 14.5 inhibitor (B)
Water	23 3	23.6
r m s d	23.5	25.0
Bond lengths (Å)	0.011	0.011
Bond angles (Å)	1.357	1.352
Ramachandran (%)	,	
Preferred	99.5	99.4
Generously	0.4	0.7
allowed	0.4	0.5
Disallowed	0.1	0.1
Values in parentheses are for the highest-resolution shell		

Table. Data collection, phasing and refinement statistics for the structure solution of CsxA with **3** and **4**.

